- Home
- EVF vs GNLX Comparison
EVF vs GNLX Comparison
Compare EVF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVF
- GNLX
- Stock Information
- Founded
- EVF 1998
- GNLX 2001
- Country
- EVF United States
- GNLX United States
- Employees
- EVF N/A
- GNLX N/A
- Industry
- EVF Investment Managers
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- EVF Finance
- GNLX Health Care
- Exchange
- EVF Nasdaq
- GNLX Nasdaq
- Market Cap
- EVF 102.2M
- GNLX 94.0M
- IPO Year
- EVF N/A
- GNLX 2023
- Fundamental
- Price
- EVF $5.63
- GNLX $2.53
- Analyst Decision
- EVF
- GNLX Strong Buy
- Analyst Count
- EVF 0
- GNLX 4
- Target Price
- EVF N/A
- GNLX $17.75
- AVG Volume (30 Days)
- EVF 93.3K
- GNLX 163.7K
- Earning Date
- EVF 01-01-0001
- GNLX 05-06-2025
- Dividend Yield
- EVF 10.68%
- GNLX N/A
- EPS Growth
- EVF N/A
- GNLX N/A
- EPS
- EVF 0.94
- GNLX N/A
- Revenue
- EVF N/A
- GNLX N/A
- Revenue This Year
- EVF N/A
- GNLX N/A
- Revenue Next Year
- EVF N/A
- GNLX N/A
- P/E Ratio
- EVF $6.74
- GNLX N/A
- Revenue Growth
- EVF N/A
- GNLX N/A
- 52 Week Low
- EVF $5.20
- GNLX $1.60
- 52 Week High
- EVF $6.84
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- EVF 47.34
- GNLX 48.27
- Support Level
- EVF $5.62
- GNLX $2.38
- Resistance Level
- EVF $5.69
- GNLX $2.60
- Average True Range (ATR)
- EVF 0.05
- GNLX 0.19
- MACD
- EVF -0.00
- GNLX 0.01
- Stochastic Oscillator
- EVF 23.08
- GNLX 38.58
About EVF Eaton Vance Senior Income Trust
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.